Fisher Asset Management
CRNX icon

Fisher Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Fisher Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.7M Sell
741,553
-21,149
-3% -$786K 0.01% 306
2026
Q1 		$27.7M Buy
762,702
+4,043
+0.5% +$181K 0.01% 293
2025
Q4 		$35.3M Buy
758,659
+302
+0% +$13.4K 0.01% 263
2025
Q3 		$31.6M Buy
758,357
+21,273
+3% +$680K 0.01% 275
2025
Q2 		$21.2M Sell
737,084
-36,263
-5% -$1.12M 0.01% 311
2025
Q1 		$25.9M Buy
773,347
+214,060
+38% +$7.99M 0.01% 290
2024
Q4 		$28.6M Buy
559,287
+77,188
+16% +$4.32M 0.01% 295
2024
Q3 		$24.6M Buy
482,099
+37,429
+8% +$1.93M 0.01% 317
2024
Q2 		$19.9M Buy
444,670
+8,647
+2% +$399K 0.01% 338
2024
Q1 		$20.4M Sell
436,023
-5,272
-1% -$206K 0.01% 335
2023
Q4 		$15.7M Buy
441,295
+387,435
+719% +$11.9M 0.01% 360
2023
Q3 		$1.6M Sell
53,860
-14,411
-21% -$297K ﹤0.01% 666
2023
Q2 		$1.23M Hold
68,271
– – ﹤0.01% 735
2023
Q1 		$1.1M Sell
68,271
-8,653
-11% -$160K ﹤0.01% 765
2022
Q4 		$1.41M Buy
76,924
+23,568
+44% +$415K ﹤0.01% 710
2022
Q3 		$1.05M Buy
+53,356
New +$1.09M ﹤0.01% 658

Other funds holding CRNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return
BSA
Braun Stacey Associates New York $3.53B AUM 63.32% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM

Fisher Asset Management's CRNX Position: Q2 2026 in Review

Fisher Asset Management reduced its Crinetics Pharmaceuticals (CRNX) stake by 2.8% in Q2 2026, selling an estimated $786K and leaving 741,553 shares worth $27.7M. The position accounts for 0.01% of the portfolio, ranked #306.

Fisher Asset Management first reported a position in CRNX in Q3 2022 and has held it in 16 quarters since. The position peaked at $35.3M in Q4 2025. 100 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Fisher Asset Management held 741,553 shares of Crinetics Pharmaceuticals worth $27.7M as of Q2 2026.
  • Fisher Asset Management sold 21,149 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $786K.
  • Crinetics Pharmaceuticals made up 0.01% of Fisher Asset Management's portfolio in Q2 2026, its #306 holding.
  • Fisher Asset Management first reported a position in Crinetics Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
  • Fisher Asset Management's Crinetics Pharmaceuticals position peaked at $35.3M in Q4 2025.
  • 100 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Fisher Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.